Sodium hyaluronate intra-articular solution for viscosupplementation in osteoarthritis and sports medicine. Play Sure Doping Free certified. CE marked.
Not to scale. Product shown enlarged for detail.
Recross is indicated for the relief of pain in osteoarthritis of the knee, hip, and shoulder in patients who have failed to respond adequately to conservative non-pharmacological therapy and simple analgesics. Administered by intra-articular injection by a qualified physician.
A single 4.0 mL injection. The effect lasts at least six months after the first injection.
Intra-articular injection by a qualified physician. Do not inject intravenously. Strict aseptic technique required.
Recross is Play Sure Doping Free certified and contains no prohibited substances. Safe for use in competitive athletes subject to WADA testing. Confirm current WADA list at time of use.
Formulation data, regulatory classification, injection parameters, and handling requirements for Recross sodium hyaluronate.
In osteoarthritic joints, endogenous HA concentration falls and the average molecular weight decreases, reducing synovial fluid viscosity. The result is impaired joint lubrication, increased cartilage stress under load, and progressive pain. Recross restores the viscoelastic properties of the synovial fluid through direct supplementation with exogenous sodium hyaluronate.
For healthcare professionals. Always refer to the current instructions for use (IFU) before clinical use.
The moderately cross-linked fraction degrades more slowly than linear hyaluronate, giving Recross prolonged cohesive residence in the joint. The effect lasts at least six months after the first injection.
Intra-articular viscosupplementation with Recross is a safe, well-tolerated procedure for patients with osteoarthritis who have not responded sufficiently to prior pharmacologic treatment. Report suspected side effects to the VSY Biotechnology Quality team at complaint@vsybiotechnology.com.
Recross is powered by VSY's proprietary HXL Hybrid XLink Technology, the first linear structured and simultaneously moderately cross-linked sodium hyaluronate, combining dispersive lubrication with cohesive shock absorption.